Herbs (Global Traditional) · Ayurveda
Priyangu (Callicarpa macrophylla) (Callicarpa macrophylla)
Moderate Evidencebotanical
Hermetica Superfood Encyclopedia
Priyangu (Callicarpa macrophylla) is an Ayurvedic medicinal plant containing phenolic compounds and flavonoids that demonstrate anti-inflammatory and antimicrobial activities. The plant's bioactive compounds work by modulating inflammatory pathways and inhibiting microbial growth through membrane disruption mechanisms.
Priyangu (Callicarpa macrophylla) is a medicinal shrub native to the Indian subcontinent belonging to the Verbenaceae family. The plant's leaves, bark, roots, and fruits are used medicinally, typically prepared as decoctions, powders, or oils containing terpenoids, flavonoids, phenols, lignans, and sterols.
No human clinical trials, RCTs, or meta-analyses have been conducted on Priyangu. Research is limited to preclinical pharmacological studies on crude extracts and isolated compounds demonstrating various activities in animal models or in vitro settings.
Traditional Ayurvedic dosages include: bark/root decoction or cold infusion at 30-50 ml for fever and bleeding; dried powder at 2-3 g mixed with milk for nourishment. No clinically studied dosages are available due to lack of human trials. Consult a healthcare provider before starting any new supplement.
Priyangu (Callicarpa macrophylla) is not consumed as a food source and therefore lacks a conventional nutritional profile of macronutrients (protein, fat, carbohydrates, fiber). Its relevance is primarily phytochemical. Key bioactive compounds identified include: • **Flavonoids**: including luteolin, apigenin, and their glycosides (concentrations vary by plant part; flowers and leaves are richest sources, estimated at 1–4% dry weight collectively). • **Triterpenoids**: including ursolic acid and oleanolic acid (bark and leaves; ~0.5–2% dry weight), contributing to anti-inflammatory and hepatoprotective activities. • **Phytosterols**: β-sitosterol and stigmasterol (trace to moderate amounts in seeds and bark). • **Tannins**: condensed and hydrolysable tannins (~3–8% dry weight in bark), responsible in part for astringent and hemostatic (anti-bleeding) properties traditionally attributed. • **Essential oil constituents**: leaves yield volatile oils (~0.2–0.5% fresh weight) containing sesquiterpenes such as β-caryophyllene, germacrene D, and caryophyllene oxide, which contribute to antimicrobial and anti-inflammatory activity. • **Phenolic acids**: gallic acid, caffeic acid, and chlorogenic acid detected in methanolic extracts of leaves and flowers (approximate total phenolic content: 40–80 mg gallic acid equivalents per gram dry extract). • **Glycosides**: callicarpenal and related iridoid-type compounds identified in trace amounts. • **Minerals**: no standardized mineral profile available; traditional texts suggest the plant accumulates calcium and iron in modest amounts, but analytical data remain limited. • **Vitamins**: no significant vitamin content documented. • **Bioavailability notes**: Many of the active flavonoids (luteolin, apigenin) have relatively low oral bioavailability (~5–10%) due to extensive first-pass metabolism and poor aqueous solubility. Traditional Ayurvedic formulations often combine Priyangu with lipid-based vehicles (ghee) or piperine-containing adjuvants (Trikatu) to enhance absorption. Tannin-rich fractions may bind dietary proteins and minerals, potentially reducing their bioavailability if co-consumed. Ursolic acid bioavailability is also limited (~1–5%) unless formulated with lipid carriers.
Priyangu's phenolic compounds and flavonoids inhibit pro-inflammatory cytokines like TNF-α and IL-6 while reducing NF-κB pathway activation. The antimicrobial effects occur through disruption of bacterial and fungal cell membranes, compromising cellular integrity. Anti-diabetic activity appears to involve α-glucosidase enzyme inhibition, reducing postprandial glucose absorption.
Current evidence for Priyangu comes primarily from preclinical animal studies and in vitro laboratory research. Anti-inflammatory studies in rodent models showed significant reduction in inflammatory markers, while antimicrobial testing demonstrated activity against various bacterial and fungal strains with MIC values ranging from 125-500 μg/ml. Anti-diabetic effects were observed in diabetic rat models with blood glucose reductions of 20-35% compared to controls. No human clinical trials have been published to date, limiting the strength of evidence for therapeutic applications.
Safety data for Priyangu is limited, with most information derived from traditional use patterns rather than systematic toxicology studies. No significant adverse effects have been reported in animal studies at standard dosing levels, but long-term safety remains unestablished. Potential interactions with diabetes medications should be considered given the plant's glucose-lowering effects. Pregnant and breastfeeding women should avoid use due to insufficient safety data, and individuals with bleeding disorders should exercise caution due to potential anticoagulant properties.
